Results from a double-blind, dose-ranging phase 2 study of maridebart cafraglutide (MariTide, Amgen) were presented at the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback